

1 **Impact of COVID-19 pandemic on the etiology and characteristics of**
2 **community-acquired pneumonia among children requiring**
3 **bronchoalveolar lavage in northern China**

4 Rui-han Liu^{1,2¶}, Yu-yan Zhang^{1¶}, Zhou-hua Lu¹, Chang-qing Shen¹, Jin Wang¹,
5 Qing Zhao¹, Tong-shu Hou³, Feng-hai Niu¹, Qing-xia Kong^{1*}, Jun Ning^{1*}, Lei
6 Yang^{1,2*}

7 ¹Affiliated Hospital of Jining Medical University, Jining Medical University,
8 Jining, Shandong, China

9 ²College of TCM, Shandong University of Traditional Chinese Medicine, Jinan,
10 Shandong, China

11 ³The Second Clinical Medical College, Binzhou Medical University, Yantai,
12 Shandong, China

13 ¶These authors contributed equally to this work.

14 * co-corresponding authors

15 **Corresponding authors**

16 E-mail: kxdqy8@sohu.com(QXK)

17 E-mail: 18678766989@163.com(JN)

18 E-mail: yanglei8224982@163.com(LY)

19 **Abstract**

20 **Background:**

21 To investigate the etiology and clinical characteristics of community-acquired
22 pneumonia (CAP) among children requiring bronchoalveolar lavage (BAL) and
23 analyze the impact of the coronavirus disease 2019 (COVID-19) pandemic on
24 the pathogen spectrum and clinical manifestations.

25 **Methods:**

26 Children <14 years old hospitalized with CAP requiring BLA were enrolled
27 between February 2019 to January 2020 and August 2021 to July 2022.
28 Multiplex reverse transcription polymerase chain reaction (mRT-PCR) was
29 used for pathogen detection. The demographic and clinical characteristics
30 were compared between different pathogen-type infection groups, and before
31 and during the COVID-19 pandemic.

32 **Results:**

33 Pathogen was detected in 91.66% (1363/1487) children. *Mycoplasma*
34 *pneumoniae*, adenovirus and human rhinovirus were the most frequently
35 detected pathogens. The frequency of detection of virus infections and
36 co-infections was decreased during the pandemic, but the detection of atypical
37 bacterial infections was increased. The clinical manifestations and the results
38 of CT scans and fiberoptic bronchoscopy showed a significant difference
39 between different types of pathogen infection, and lung inflammation was
40 reduced during the COVID-19 pandemic compared with before the pandemic.

41 **Conclusions:**

42 *M. pneumoniae* infection might be the greatest pediatric disease burden
43 leading to CAP in northern China. Wearing masks and social distancing in
44 public places during the COVID-19 pandemic effectively reduced the
45 transmission of respiratory viruses, but it did not reduce the infection rate of *M.*
46 *pneumoniae*. In addition, these interventions significantly reduced lung
47 inflammation in children compared with before the pandemic.

48 **Introduction**

49 Community-acquired pneumonia (CAP) is a common infection that presents a
50 serious public health threat among children under 5 years of age. CAP was
51 responsible for 13.9% of childhood deaths among the under-5s worldwide in
52 2019[1]. Although this was more than 1,001,000 fewer deaths compared with
53 the year 2000, the number of complicated and severe pneumonia cases has
54 increased considerably over the past two decades[2,3]. Following the
55 introduction of the pneumococcal conjugate vaccine and the *Haemophilus*
56 *influenzae* type b vaccine, respiratory viruses and atypical bacteria have
57 become the most frequent etiologic agents in recent years[4].

58 The outbreak of coronavirus disease 2019 (COVID-19) constitutes a
59 substantial health burden across the globe. To control the COVID-19
60 pandemic, governments around the world implemented a series of
61 non-pharmaceutical interventions (NPIs), such as mandated facial masks,
62 encouraged social distancing, remote working, online teaching, stay-at-home
63 orders and travel restrictions. Studies have shown that the preventive
64 measures useful in containing COVID-19 also seemed to be effective in
65 preventing the transmission of other respiratory viruses[5-11]. Considering the
66 impact of etiology on disease severity, mortality and long-term sequelae in
67 children with CAP[12], it is necessary to identify the causative pathogen.

68 Nasopharyngeal swabs or aspirate specimens are usually used for
69 pathogen detection in children with CAP. However, the detection of

70 microorganisms from the upper respiratory tract may not directly correlate with
71 the pathogenic agents of pneumonia[13]. Over the past two decades,
72 fiberoptic bronchoscopy (FB) and bronchoalveolar lavage (BAL) have become
73 important diagnostic and therapeutic procedures for severe pneumonia.
74 Bronchoalveolar lavage fluid (BALF) collected directly from the foci of
75 inflammation can be used as reliable samples for pathogen identification[14].
76 Furthermore, advances in molecular detection technology have contributed to
77 the rapid and accurate pathogen identification. Automated capillary
78 electrophoresis combined with multiplex reverse transcription polymerase
79 chain reaction (mRT-PCR) has been developed to detect microorganisms, at
80 reasonable cost and acceptable levels of sensitivity and specificity[15].

81 In this study, we report and discuss the impact of the COVID-19 pandemic
82 on the spectrum of common respiratory pathogens among children with CAP
83 requiring FB plus BAL in northern China. Additionally, changes in the pathogen
84 spectrum and the clinical manifestations in the children were analyzed
85 systematically and compared prior to the COVID-19 pandemic (February 2019
86 to January 2020) and during the COVID-19 pandemic (August 2021 to July
87 2022).

88 **Materials and methods**

89 **Ethics approval**

90 This study was approved by the Ethics Committee of the Affiliated Hospital of
91 Jining Medical University (No.: 2020C076).

92 **Study population**

93 Between February 2019 to January 2020 and August 2021 to July 2022, a total
94 of 1487 children under the age of 14 who required BAL were included in our
95 study. It was ensured by experienced physicians that the following inclusion
96 criteria were met. (1) All of the children were in the acute stage of pneumonia.
97 (2) Symptoms persisted for at least 7 days after the initiation of treatment
98 and/or the patient was not responding to treatment, or breathing was labored,
99 or the child became distressed or agitated, or their oxygen saturation level was
100 < 92%. (3) Auscultation revealed decreased/absent breath sounds, or tubular
101 breath sounds, and or a repeated fixed wheeze. (4) Radiographic inspection
102 revealed pulmonary atelectasis, or pulmonary emphysema, or mediastinal
103 emphysema, or pulmonary consolidation. Exclusion criteria were as follows:
104 children with immunodeficiency disease, congenital heart disease,
105 tracheostomy tube, cystic fibrosis, hemopoietic system malignant tumor,
106 recent hematopoietic stem-cell or solid-organ transplant, children with an
107 alternative respiratory disorder diagnosis or newborns less than 1 month old.
108 Written informed consent was obtained from parents/guardians before children
109 underwent FB plus BAL.

110 **Sample and data collection**

111 For the purpose of treatment, FB combined with BAL was performed by
112 experienced bronchoscopists according to the recommendation of the
113 European Respiratory Society Task Force[16]. Approximately 3 mL of BALF

114 was collected from each patient and the samples were aliquoted and stored at
115 -80°C within 2 hours simultaneously. Diagnosis of the morphology under
116 bronchoscopy was made by two experienced physicians[17,18].

117 The presence of pulmonary consolidation, infiltration, pleural effusion and
118 pericardial effusion in the CT scans was considered evidence of
119 pneumonia[19]. The CT scans were reviewed by three senior radiologists
120 independently to ensure the accuracy and consistency of the diagnosis. The
121 other clinical data were extracted from electronic medical records after the
122 patient was discharged.

123 **Pathogen detection**

124 The SureX 13 respiratory pathogen multiplex kit (Ningbo Health Gene
125 Technologies Ltd.) was used to simultaneously detect common virus and
126 atypical bacteria in 200 µL of BALF. The mRT-PCR products were analyzed on
127 the Applied Biosystems 3500Dx Genetic Analyzer with LIZ500 as the internal
128 standard, and then analyzed with GeneMapper 4.1 software (Thermo Fisher
129 Scientific, Waltham, MA, USA).

130 A viral or atypical bacterial pathogen was considered to be present if
131 influenza A virus (Flu A, including 2009 H1N1 pandemic and H3N2), influenza
132 B virus (Flu B), parainfluenza virus (PIV), adenovirus (AdV), respiratory
133 syncytial virus (RSV), human rhinovirus (HRV), human metapneumovirus
134 (hMPV), human bocavirus (HBoV), coronavirus (CoV), *Mycoplasma*
135 *pneumoniae* or *Chlamydomphila pneumoniae* was detected in the BALF.

136 Co-infection was considered when two or more viral or atypical bacterial
137 pathogens were detected in one child.

138 **Statistical analysis**

139 Considering the similar clinical features observed between children with
140 virus–virus co-infections and single virus infections, these cases were
141 combined into the virus group in the tables. This also applied to those with one
142 or two atypical bacterial infections, who were combined in the atypical
143 bacterium group. The clinical characteristics of enrolled children were stratified
144 and described according to the following groups: virus or atypical bacterium
145 only infection, and co-infection (virus–atypical bacterium infections).

146 All statistical analyses were performed using SAS software, version 9.4
147 (SAS Institute Inc., NC, USA). The median and quartile [M (P25, P75)] values
148 were used to describe quantitative data with a non-normal distribution, and the
149 frequency (component ratio) [n (%)] was used to describe classified data. The
150 Chi-squared test was used to analyze differences in sex, age, the season of
151 disease onset and the infecting pathogens between samples collected before
152 and during the COVID-19 pandemic. The Kruskal–Wallis H test was used to
153 compare the time from illness onset to admission, the duration of
154 hospitalization, and the presence of a fever and cough in different groups
155 between different time periods. Fisher's exact test was used to compare the
156 difference in the proportion of different pathogens between samples taken
157 before and during the COVID-19 pandemic. Trends in the infection rates of

158 various pathogens in different age groups were assessed by the
159 Cochran–Armitage trend test. The differences in clinical manifestations, CT
160 scans and FB results between the various groups and different time periods
161 were also analyzed by Fisher's exact test. A probability (p) value less than 0.05
162 was considered statistically significant. For pairwise comparison of multiple
163 groups of samples, Bonferroni correction was used to inspect the standard of
164 each comparison, $\alpha' = 0.01667$ (0.05/3).

165 **Results**

166 **Demographic characteristics**

167 From February 2019 to January 2020 and August 2021 to July 2022, 696 and
168 791 children were enrolled in this study, respectively (Table 1). A total of
169 54.74% of the children were boys, and the median age was 70.51 ± 32.79
170 months. The median time from illness onset to admission and the median
171 duration of hospitalization were 8 (6,10) days and 7 (6,9) days, respectively.
172 The proportion of children undergoing FB combined with BAL gradually
173 increased with age ($\chi^2/Z=54.0288$, $P<0.001$), and the proportion of children
174 affected during autumn was significantly higher than that in the other seasons.

175 Compared with before the COVID-19 pandemic, the median time from
176 illness onset to hospitalization was reduced [8 (6,11) days vs 7 (6,10) days;
177 $P=0.0031$] and the median hospitalization time was also reduced [8 (7,9) days
178 vs 7 (6,8) days; $P<0.001$] in the children enrolled during the COVID-19
179 pandemic. During the COVID-19 pandemic, the pathogen detection rate

180 **Table 1 Demographic characteristics of children with community-acquired pneumonia requiring Flexible bronchoscopy and bronchoalveolar lavage**

Variables	Total	Before	Ongoing	X²/Z	P
Number	1487	696	791	-	-
Sex (male), No. (%) ^a	814(54.74)	385(55.32)	429(54.24)	0.1746	0.676
Time from illness onset to admission (days), mean(P25, P75) ^b	8(6,10)	8(6,11)	7(6,10)	8.748	0.0031
Duration of hospitalization (days), mean(P25, P75) ^b	7(6,9)	8(7,9)	7(6,8)	48.1227	<0.001
Age (mo), mean ± SD ^a	70.51±32.79	64.41±32.43	75.87±32.19		
age < 3 yrs, No. (%)	229(15.40)	149(21.41)	80(10.11)	54.0288	<0.001
3 yrs. ≤ age < 5 yrs, No. (%)	357(24.01)	170(24.43)	187(23.64)		
5 yrs. ≤ age < 7 yrs, No. (%)	427(28.72)	207(29.74)	220(27.81)		
7 yrs. ≤ age < 14 yrs, No. (%)	474(31.88)	170(24.43)	304(38.43)		
Incident season, No. (%) ^a					
Spring (Mar, Apr, May)	170 (11.43)	116(16.67)	54(6.83)	40.2873	<0.001
Summer (Jun, Jul, Aug)	237 (15.94)	89(12.79)	148(18.71)		
Fall (Sep, Oct, Nov)	640(43.04)	291(41.81)	349(44.12)		
Winter (Dec, Jan, Feb)	440(29.59)	200(28.74)	240(30.34)		

181 Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the total
 182 number.

183 a. Chi-square test was used to analyze the differences in gender, age and onset seasons between before COVID-19 pandemic and during COVID-19

184 pandemic.

185 **b.** Kruskal-Wallis H Test was used to compare the time from illness onset to admission and duration of hospitalization in different groups between different

186 period.

187 decreased from 20% to ~10% in children under 3 years of age and increased
188 from 25% up to ~40% in children aged over 7 years. There was also a
189 statistical difference in the season of illness onset among the children
190 ($\chi^2/Z=40.2873$, $P<0.001$), with a lower incidence of disease in spring (16.67%
191 vs 6.83%) and a higher incidence in summer (12.79% vs 18.71%) during the
192 COVID-19 pandemic (Table 1).

193 **Pathogen spectrum**

194 Among the enrolled children, ≥ 1 pathogen was detected in 91.66% (1363/1487)
195 of children and the pathogen detection rate gradually increasing with age
196 ($Z=-6.425$, $P<0.001$). The specific pathogens detected are listed in Table 2,
197 sorted by descending detection rates. AdV (n=64, 4.30%), HRV (n=41, 2.76%),
198 PIV (n=21, 1.41%) and Flu B (n=21, 1.41%) were the most common viral
199 pathogens among the enrolled cases. There were statistically significant
200 differences in the age of children infected with viruses, with the number of
201 children infected with viruses decreasing with increased age, except for Flu B
202 ($P=0.1927$) and hMPV ($P=0.1447$). Children younger than 3 years were more
203 vulnerable to AdV, PIV and RSV infection, whereas children older than 3 years
204 were more susceptible to atypical bacterial infection. A total of 1254 (84.33%)
205 cases were found to be infected with *M. pneumoniae*, and the number of
206 children with *M. pneumoniae* infection increased with age ($Z=-10.2742$,
207 $P<0.001$).

208 Compared with before the COVID-19 pandemic, the number of children

Table 2 Prevalence of causative respiratory pathogen according to age groups in children performed with FOB combined with BAL

Pathogen Detected	Total No. (%)	< 3 years No. (%)	3–5 years No. (%)	5–7 years No. (%)	7–14 years No. (%)	Z	p
Participants, n	1487	229	357	427	474	-	-
≥1 pathogen detected	1363(91.66)	186(81.22)	319(89.36)	407(95.32)	451(95.15)	-6.425	<0.001
Virus							
AdV ^a	64(4.30)	19(8.30)	25(7.00)	13(3.04)	7(1.48)	4.9844	<0.001
HRV ^a	41(2.76)	10(4.37)	11(3.08)	11(2.58)	9(1.90)	1.8833	0.0298
PIV ^a	21(1.41)	12(5.24)	5(1.40)	2(0.47)	2(0.42)	4.6023	<0.001
Flu B	21(1.41)	5(2.18)	2(0.56)	11(2.58)	3(0.63)	0.8681	0.1927
RSV ^a	19(1.28)	11(4.80)	2(0.56)	4(0.94)	2(0.42)	3.8454	<0.001
Flu A ^a	10(0.67)	6(2.62)	2(0.56)	0(0.00)	2(0.42)	2.9073	0.0018
HBoV ^a	8(0.54)	5(2.18)	1(0.28)	1(0.23)	1(0.21)	2.7325	0.0031
hMPV	8(0.54)	2(0.87)	2(0.56)	3(0.7)	1(0.21)	1.0593	0.1447
CoV ^a	2(0.13)	1(0.44)	1(0.28)	0(0.00)	0(0.00)	1.6974	0.0448
Atypical bacteria							
<i>M.pneumonia</i> ^a	1254(84.33)	142(62.01)	291(81.51)	381(89.23)	440(92.83)	-10.2742	<0.001
<i>C.pneumoniae</i>	4(0.27)	1(0.44)	0(0.00)	1(0.23)	2(0.42)	-0.4335	0.3323

210 Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the total
 211 number.

212 ^a $p < 0.05$, Cochran-Armitage Trend Test was used to compare trends of infection rates of various pathogens in different age groups.

Table 3 Distribution of various pathogens in children patients performed with FOB combined with BAL

Pathogen Detected	Total, No. (%)	Before, No. (%)	Ongoing, No. (%)		
Participants, n	1487	696	791	X²/Z	p
Virus	107(7.20)	69(9.91)	38(4.80)	28.1146	<0.001
Atypical bacteria	1177(79.15)	515(73.99)	662(83.69)		
Co-infection	79(5.31)	51(7.33)	28(3.54)		
No pathogenic detected	124(8.34)	61(8.76)	63(7.96)		
Virus				p	
AdV ^a	64(4.30)	40(5.75)	24(3.03)	0.0105	
HRV ^a	41(2.76)	29(4.17)	12(1.52)	0.0022	
PIV	21(1.41)	13(1.87)	8(1.01)	0.1894	
Flu B ^a	21(1.41)	15(2.16)	6(0.76)	0.0271	
RSV	19(1.28)	8(1.15)	11(1.39)	0.8182	
Flu A ^a	10(0.67)	10(1.44)	0(0.00)	0.0005	
HBoV ^a	8(0.54)	7(1.01)	1(0.13)	0.0293	
hMPV	8(0.54)	3(0.43)	5(0.63)	0.7303	
CoV	2(0.13)	2(0.29)	0(0.00)	0.2189	
Atypical bacteria				p	
<i>M.pneumonia</i> ^a	1254(84.33)	564(81.03)	690(87.23)	0.0013	
<i>C.pneumoniae</i> ^a	4(0.27)	4(0.57)	0(0.00)	0.0478	

214 Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the number.

215 ^a $p < 0.05$, Fisher's Exact Test was used to compare the differences between alone and co-infection of each pathogen in different period.

216 infected with AdV (5.75% vs 3.03%, $P=0.0105$), HRV (4.17% vs 1.52%,
217 $P=0.0022$), Flu B (2.16% vs 0.76%, $P=0.0271$), Flu A (1.44% vs 0.00%,
218 $P=0.0005$) and HBoV (1.01% vs 0.13%, $P=0.0293$) decreased significantly.
219 Therefore, the total proportion of cases of viral infection (9.91% vs 4.80%) and
220 co-infection (7.33% vs 3.54%) decreased significantly. Whereas the proportion
221 of cases of *M. pneumoniae* infection had a further increasing that compared
222 with before the pandemic (87.23% vs 81.03%, $P=0.0013$) (Table 3).

223 **Clinical characteristics between three infection groups**

224 Children with viral infection showed the shortest duration of fever [4 (0,6) days],
225 while those with atypical bacterial infection [7 (5,9) days vs 4 (0,6) days,
226 $P<0.001$] or co-infection [7 (4,10) days vs 4 (0,6) days, $P=0.0002$] showed
227 longer duration of fever, and the differences among the three groups were
228 statistically significant ($P<0.001$). The incidence of wheezing in children
229 infected with virus (18.69% vs 3.91%, $P<0.001$) and those with co-infection
230 (15.19% vs 3.91%, $P=0.0001$) was significantly higher than in those with
231 atypical bacterial infection (3.91%). Compared with the atypical bacterial
232 infection group, viral infection made children more prone to dyspnea (8.41% vs
233 1.44%, $P=0.0001$), diarrhea (15.89% vs 6.73%, $P=0.0019$), rhonchi (47.66%
234 vs 28.63%, $P=0.0003$) and chest indrawing (9.35% vs 1.7%, $P=0.0001$).
235 Decreased breath sounds (59.64%) and rales (66.10%) were the most
236 common signs in the atypical bacterial infection group. No remarkable
237 differences in the duration of cough, fatigue, lack of appetite, abdominal pain,

Table 4 Comparison of clinical and laboratory findings according to respiratory pathogens in children performed with FOB combined with BAL

Characteristic	Total N=1363	Virus ¹ N=107	Atypical Bacteria ² N=1177	Co-infection ³ N=79	P value	P value ^c (1-2)	P value ^c (1-3)	P value ^c (2-3)	
Clinical data									
Duration of fever,mean(P25, P75) ^a	7(5,8)	4(0,6)	7(5,9)	7(4,10)	<0.001	<0.001	0.0002	0.7161	
Duration of cough,mean(P25, P75) ^a	7(5,9)	6(4,13)	7(5,9)	8(5,11)	0.3451	0.5847	0.8112	0.1543	
Fatigue ^b	17(1.25)	3(2.80)	12(1.02)	2(2.53)	0.1035	0.1228	1	0.2184	
Dyspnea ^b	29(2.13)	9(8.41)	17(1.44)	3(3.80)	0.0001	0.0001	0.2422	0.1262	
Wheezing ^b	78(5.72)	20(18.69)	46(3.91)	12(15.19)	<0.001	<0.001	0.5621	0.0001	
Lack of appetite ^b	830(60.9)	66(61.68)	719(61.09)	45(56.96)	0.7557	1	0.5476	0.4769	
Abdominal pain ^b	227(16.65)	15(14.02)	201(17.08)	11(13.92)	0.6354	0.5000	1	0.5375	
Diarrhea ^b	100(7.34)	17(15.89)	75(6.37)	8(10.13)	0.0019	0.0012	0.2845	0.2356	
Chest pain ^b	40(2.93)	4(3.74)	33(2.80)	3(3.80)	0.5852	0.5424	1	0.4907	
Physical sign									
Decreased breath sounds ^b	770(56.49)	35(32.71)	702(59.64)	33(41.77)	<0.001	<0.001	0.2208	0.0021	
Rales ^b	887(65.08)	60(56.07)	778(66.10)	49(62.03)	0.0957	0.0436	0.4535	0.4640	
Rhonchi ^b	415(30.45)	51(47.66)	337(28.63)	27(34.18)	0.0003	<0.001	0.0727	0.3062	

	Tachypnea ^b	47(3.45)	5(4.67)	39(3.31)	3(3.80)	0.571	0.4065	1	0.744
	Chest indrawing ^b	33(2.42)	10(9.35)	20(1.70)	3(3.80)	0.0001	<0.001	0.2437	0.1718
CT scan									
	Consolidation ^b	1034(75.86)	60(56.07)	926(78.67)	48(60.76)	<0.001	<0.001	0.5505	0.0007
	Single lobar infiltrate ^b	519(38.08)	30(28.04)	465(39.51)	24(30.38)	0.0222	0.0222	0.7462	0.1215
	Multilobar infiltrates (unilateral) ^b	377(27.66)	19(17.76)	333(28.29)	25(31.65)	0.0408	0.0177	0.0359	0.5214
	Multilobar infiltrates (bilateral) ^b	436(31.99)	50(46.73)	358(30.42)	28(35.44)	0.0024	0.0007	0.135	0.3781
	Pleural effusion ^b	236(17.31)	13(12.15)	211(17.93)	12(15.19)	0.2979	0.1445	0.6644	0.6486
	Pericardial effusion ^b	37(2.71)	4(3.74)	29(2.46)	4(5.06)	0.2135	0.3478	0.7244	0.1485
Fiberoptic bronchoscopy									
	Mucosal hyperemia and/or edema ^b	820(60.16)	69(64.49)	714(60.66)	37(46.84)	0.0348	0.4699	0.0174	0.0176
	Mucosal erosion and/or necrosis ^b	543(39.84)	38(35.51)	463(39.34)	42(53.16)	0.0348	0.4699	0.0174	0.0176
	Bronchial mucus plugs ^b	224(16.43)	2(1.87)	214(18.18)	8(10.13)	<0.001	<0.001	0.0193	0.0919
	Plastic bronchitis ^b	171(12.55)	2(1.87)	162(13.76)	7(8.86)	0.0002	<0.001	0.0382	0.3048
	Bronchial atresia ^b	23(1.69)	6(5.61)	14(1.19)	3(3.80)	0.0023	0.0043	0.7352	0.0861
	Bronchiectasis ^b	11(0.81)	5(4.67)	5(0.42)	1(1.27)	0.0006	0.0007	0.2433	0.3233

239 Group 1, Virus alone infection; group 2, Atypical Bacteria alone infection; group 3, Virus-Atypical bacteria co-infection.

- 240 a. Kruskal-Wallis H tests were conducted to compare groups.
- 241 b. Fisher exact tests were conducted to compare groups.
- 242 c. Bonferroni correction was conducted to pairwise comparison of multiple groups of samples.

243 chest pain and tachypnea were observed between the three groups (Table 4).

244 In CT scan findings, both consolidation and infiltration revealed prominent
245 differences among the different infection groups. Atypical bacterial infection
246 was most likely to cause consolidation ($P < 0.001$) and single lobar infiltration
247 ($P = 0.0222$). Compared with the atypical bacterial infection group, the virus
248 infection group was more likely to lead to bilateral multilobar infiltration
249 (46.73% vs 30.42%, $P = 0.0007$), whereas unilateral multilobar infiltration was
250 more common in the atypical bacterial infection group than in the virus
251 infection group (28.29% vs 17.76%, $P = 0.0177$) or the co-infection group
252 (31.65% vs 17.76%, $P = 0.0359$) (Table 4).

253 The FB findings showed that compared with the viral infection and atypical
254 bacterial infection groups, the co-infection group presented more severe
255 tracheal mucosal injury. The proportion of more severe mucosal erosion
256 and/or necrosis was the highest in co-infection group (53.16% vs 35.51%,
257 $P = 0.0174$; 53.16% vs 39.34%, $P = 0.0176$). Compared with the viral infection
258 group, bronchial mucus plugs and plastic bronchitis were more frequently
259 detected in children with atypical bacterial infections (18.18% vs 1.87%,
260 $P < 0.001$) and co-infections (10.13% vs 1.87%, $P = 0.0193$). Compared with the
261 atypical bacterial infection group, virus infection was more likely to give rise to
262 alterations in bronchial lumen morphology, which included bronchial atresia
263 (5.61% vs 1.19%, $P = 0.0043$) and bronchiectasis (4.67% vs 0.42%, $P = 0.0007$)
264 (Table 4).

265 **Clinical characteristics before and during the COVID-19 pandemic**

266 Compared with before the COVID-19 pandemic, clinical symptoms and
267 pulmonary signs in the enrolled children during the pandemic showed a shorter
268 duration of cough [7 (5,10) days vs 6 (4,9) days; $P<0.001$], a decreased
269 proportion of rhonchi dyspnea (38.11% vs 23.76%, $P<0.001$) and chest
270 indrawing (3.46% vs 1.51%, $P=0.0216$), but an increased proportion of chest
271 pain (1.89% vs 3.85%, $P=0.0364$), decreased breath sounds (47.87% vs
272 64.01%, $P<0.001$) and rales (49.92% vs 78.30%, $P<0.001$). CT scans
273 revealed that the proportions of consolidation (91.76% vs 57.64%, $P<0.001$)
274 and unilateral multilobar infiltrates (32.55% vs 22.05%, $P<0.001$) were higher
275 than before the COVID-19 pandemic, but the proportions of bilateral multilobar
276 infiltrates (28.57% vs 35.91%, $P=0.0043$) and pleural effusion (13.74% vs
277 21.42%, $P=0.0002$) were lower than before the COVID-19 pandemic. The FB
278 findings revealed an increased proportion of mucosal hyperemia and/or edema
279 (27.09% vs 89.01%, $P<0.001$), which corresponded to the decreased
280 proportion of mucosal erosion and/or necrosis (72.91% vs 10.99%, $P<0.001$).
281 Despite a significant increase in the proportion of bronchial mucus plugs
282 (13.70% vs 18.82%, $P=0.0126$), there was a significant reduction in bronchial
283 atresia (3.31% vs 0.27%, $P<0.001$) and bronchiectasis (1.57% vs 0.14%,
284 $P=0.0039$). The above results suggest that lung inflammation in the enrolled
285 children was significantly alleviated compared with before the COVID-19
286 pandemic (Table 5).

Table5 Comparison of clinical and laboratory findings before and during COVID-19 pandemic in children performed with FOB combined with BAL

Characteristic	Total n=1363	Before n=635	Ongoing n=728	P value
Clinical data				
Duration of fever,mean(P25, P75) ^a	7(5,8)	7(5,9)	7(5,8)	0.4202
Duration of cough,mean(P25, P75) ^a	7(5,9)	7(5,10)	6(4,9)	<0.001
Fatigue ^b	17(1.25)	10(1.57)	7(0.96)	0.337
Dyspnea ^b	29(2.13)	19(2.99)	10(1.37)	0.0581
Wheezing ^b	78(5.72)	41(6.46)	37(5.08)	0.2941
Lack of appetite ^b	830(60.9)	379(59.69)	451(61.95)	0.4043
Abdominal pain ^b	227(16.65)	98(15.43)	129(17.72)	0.2747
Diarrhea ^b	100(7.34)	50(7.87)	50(6.87)	0.5323
Chest pain ^b	40(2.93)	12(1.89)	28(3.85)	0.0364
Physical sign				
Decreased breath sounds ^b	770(56.49)	304(47.87)	466(64.01)	<0.001
Rales ^b	887(65.08)	317(49.92)	570(78.30)	<0.001
Rhonchi ^b	415(30.45)	242(38.11)	173(23.76)	<0.001

Tachypnea ^b	47(3.45)	19(2.99)	28(3.85)	0.4576
Chest indrawing ^b	33(2.42)	22(3.46)	11(1.51)	0.0216
CT scan				
Consolidation ^b	1034(75.86)	366(57.64)	668(91.76)	<0.001
Single lobar infiltrate ^b	519(38.08)	245(38.58)	274(37.64)	0.7374
Multilobar infiltrates (unilateral) ^b	377(27.66)	140(22.05)	237(32.55)	<0.001
Multilobar infiltrates (bilateral) ^b	436(31.99)	228(35.91)	208(28.57)	0.0043
Pleural effusion ^b	236(17.31)	136(21.42)	100(13.74)	0.0002
Pericardial effusion ^b	37(2.71)	15(2.36)	22(3.02)	0.5065
Fiberoptic bronchoscopy				
Mucosal hyperemia and/or edema ^b	820(60.16)	172(27.09)	648(89.01)	<0.001
Mucosal erosion and/or necrosis ^b	543(39.84)	463(72.91)	80(10.99)	<0.001
Bronchial mucus plugs ^b	224(16.43)	87(13.70)	137(18.82)	0.0126
Plastic bronchitis ^b	171(12.55)	86(13.54)	85(11.68)	0.3255
Bronchial atresia ^b	23(1.69)	21(3.31)	2(0.27)	<0.001
Bronchiectasis ^b	11(0.81)	10(1.57)	1(0.14)	0.0039

288 Data are no. (%) of children, unless otherwise indicated. Percentages were calculated using the number of children with available data, rather than the number.

289 a. Kruskal-Wallis H tests were conducted to compare groups.

290 b. Fisher exact tests were conducted to compare groups.

291 Discussion

292 Respiratory pathogen detection in nasopharyngeal swabs, oropharyngeal
293 swabs and even endotracheal aspirates may not fully represent the etiology of
294 pneumonia[20]. Thus, most children with CAP may not receive treatment
295 based on a reliable etiological diagnosis. Furthermore, the pathogen spectrum
296 of respiratory tract infections is affected by age, geography, and environmental,
297 social, economic and other factors. It is therefore necessary to definitively
298 address the spectrum of respiratory pathogens involved in pediatric CAP. The
299 aim of this study was to evaluate the etiologies in children with CAP requiring
300 BAL. In addition, the influence of the COVID-19 pandemic on the pathogens
301 and the clinical manifestations in the children were analyzed.

302 We found that the positive rate of pathogen detection was 91.66%. The high
303 etiological detection rate may be mainly attributable to our use of mRT-PCR on
304 specimen from the foci of inflammation. The most common pathogen was *M.*
305 *pneumoniae*, which was detected in more than four-fifths of all cases, with a
306 remarkable over-representation among children older than 3 years of age. This
307 proportion was higher than that reported in other studies (Lee *et al.* 45.3% in
308 South Korea[4] and Gao *et al.* 37.5% in north China[3]. Considering that
309 patients who required BAL in addition to intravenous medical treatment had
310 more severe pneumonia, this difference may partly be explained by the
311 differences in the studied populations.

312 Virus was detected in 12.51% (186/1487) of our enrolled cases. Unlike our

313 results, one or more viruses were detected in 73% of children hospitalized for
314 CAP in the United States[21]. Furthermore, a higher percentage of children
315 (94.3%) were reported with severe acute respiratory infection in China during
316 the 2009 H1N1 pandemic and post-pandemic period[22]. With the differences
317 in study sites, populations, as well as study years and duration, the proportions
318 varied largely between studies. Of the 186 children infected with virus, AdV
319 was the most prevalent in the present study representing 34.41% (64/186) of
320 cases, which was in line with a study in Cameroon among children with severe
321 acute respiratory infections[23]. However, the majority of similar studies
322 reported RSV as the most commonly detected viral pathogen[20,21]. In the
323 present study, RSV ranked fifth with a relatively low positive detection rate of
324 10.22% (19/186). Co-infections were observed in nearly half of the patients
325 (42.47%, 79/186) that tested positive for virus infection. This suggests that
326 severe viral-related CAP is often accompanied by atypical bacterial infection.

327 The COVID-19 pandemic and the NPIs undertaken during the pandemic
328 significantly affected the transmission of common respiratory pathogens.
329 Compared with before the COVID-19 pandemic, the overall detection rate of
330 viral pathogens was lower during the COVID-19 pandemic. However, the
331 detection rate of atypical bacterial pathogens increased. The decreased
332 detection of AdV, HRV, Flu B, Flu A and HBoV greatly contributed to the
333 overall reduction in viral pathogens. In accordance with our results, a
334 significant decrease in the detection of AdV, Flu B and Flu A was also

335 observed in children with a lower respiratory tract infection during the
336 COVID-19 pandemic in southern China[5] and a considerable reduction in all
337 viral respiratory infections was observed in a large Italian tertiary hospital[6]. In
338 a study conducted in southern China, the detection rates of *M. pneumoniae*
339 using nasopharyngeal swabs of inpatients with acute respiratory infection were
340 also unprecedentedly reduced from 20% in 2019 to 1.0% in 2020[7]. However,
341 another study using BALF from a city in northern China, showed that *M.*
342 *pneumoniae* was the most frequently detected pathogen, at a rate of up to
343 73.55%[24]. Furthermore, the detection of *M. pneumoniae* further increased
344 despite the NPIs that were adopted during the COVID-19 pandemic. The main
345 reason for this phenomenon might be the long-term colonization of *M.*
346 *pneumoniae* in the upper respiratory tract[25].

347 In aspect to clinical manifestations, we found that children with atypical
348 bacterial infections more frequently displayed a longer duration of fever, and a
349 higher proportion of decreased breath sounds and rales. However, dyspnea,
350 wheezing, diarrhea, rhonchi and chest indrawing were more frequent among
351 children with a viral infection. Similar to other studies[26], compared with
352 children with viral pneumonia, *M. pneumoniae*-positive children were
353 significantly more likely to report a long duration of symptoms before
354 hospitalization, and decreased breath sounds and rales, but were less likely to
355 report dyspnea, wheezing, diarrhea, rhonchi and chest indrawing. Such
356 findings may help inform clinicians of the preliminary differentiation between

357 viral and atypical bacterial infections.

358 On CT scans, consolidation and unilateral lung infiltration were often seen in
359 the atypical bacterial infection group, whereas bilateral lung infiltration was
360 more common in the viral infection group, suggesting that pulmonary
361 inflammation caused by *M. pneumoniae* is relatively limited to unilateral lung
362 tissue, while viral infection affected bilateral lung tissues in nearly half of the
363 children. This finding was consistent with another study that compared the
364 radiographic findings of children hospitalized for CAP with and without *M.*
365 *pneumoniae* using data from the EPIC study[27]. FB results indicated more
366 serious inflammatory changes in the mucosa, increasing the likelihood of this
367 condition developing into bronchial mucus plugs and even bronchial dendritic
368 casts in *M. pneumoniae*-infected children. The presence of bronchial mucus
369 plugs, as detected by FB, is independently associated with a longer time
370 period to radiographic clearance in patients with refractory *M. pneumoniae*
371 pneumonia[28]. Wang *et al.* reported that in 86.6% of children with plastic
372 bronchitis the causative agent was *M. pneumoniae*[29] and this result was
373 consistent with our findings. Bronchial atresia and/or bronchiectasis of the
374 distal airway mostly occurred in children infected with virus. Despite few
375 articles related to bronchial lumen morphological changes during the acute
376 stage of pneumonia, our experienced bronchoscopists found that bronchial
377 lumen dilation can be reversed with appropriate treatment. It was unfortunate
378 that bronchial atresia was usually not reversible. Thus, the results highlighted

379 the necessity for careful management and long-term follow-up of patients with
380 mucus plugs, plastic bronchitis and bronchial lumen morphological changes.

381 Several studies have reported the impact of the COVID-19 pandemic on the
382 pathogen spectrum of respiratory tract infections in children[5-7,24], but the
383 corresponding differences in clinical manifestations have rarely been studied.
384 During the COVID-19 pandemic, we found a decreased proportion of rhonchi,
385 chest indrawing, bilateral lung infiltrates and bronchial lumen morphological
386 changes, but a significantly higher proportion of decreased breath sounds,
387 rales, consolidation, unilateral lung infiltrates and bronchial mucus plugs.
388 Considering that the clinical manifestations of the children were consistent with
389 a higher detection rate of *M. pneumoniae*, a possible explanation for this
390 difference was a decrease in viral infection accompanied by an increase in *M.*
391 *pneumoniae* infection. Therefore, wearing masks and social distancing in
392 public places could effectively reduce the transmission of respiratory viruses,
393 but did not reduce the infection rate of *M. pneumoniae*. Compared with before
394 the COVID-19 pandemic, fewer children with bilateral multilobar infiltrates and
395 pleural effusion were detected by CT scans, and mild inflammatory changes in
396 the mucosa and decreased lumen morphological changes were detected by
397 FB. Therefore, it is reasonable to deduce that the NPIs during the COVID-19
398 pandemic significantly alleviated lung inflammation compared with before the
399 pandemic.

400 Several limitations should be taken into consideration in this present study.

401 First, our study was limited to children requiring BALF and did not include
402 children receiving medical therapy alone or in need of intensive care, and
403 therefore does not fully represent the distribution of characteristics of all CAP
404 pathogens. Second, although testing for common respiratory viruses and
405 atypical bacteria, bacterial detection was restricted to the panel of organisms
406 covered by the SureX 13 respiratory pathogen multiplex kit. This may have
407 resulted in underestimation of the overall detection rate for pathogens. Third,
408 due to the implementation of NPIs, our sample collection time was interrupted
409 and were not able to identify the season-dependent changes in the occurrence
410 of CAP caused by each etiology.

411 Despite these limitations, our study suggest that *M. pneumoniae* infection
412 might be the greatest pediatric disease burden leading to CAP in northern
413 China. Wearing masks and social distancing in public places can effectively
414 reduce the transmission of respiratory viruses, but cannot reduce the infection
415 rate of *M. pneumoniae*. In addition, the NPIs during the COVID-19 pandemic
416 significantly reduced lung inflammation compared with before the pandemic.
417 Our identifying changes in the pathogen spectrum and clinical characteristics
418 might improve clinical management practices and emphasize the protective
419 value of wearing masks and social distancing in children with
420 Community-acquired pneumonia in children.

421 **Acknowledgments** The authors would like to thank the clinical staff,
422 specifically the medical doctors and nurses, for their help with collecting clinical
423 specimens, and all of the children and their parents for their participation and
424 cooperation.

425 **References**

- 426 1. Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al.
427 Global, regional, and national causes of under-5 mortality in 2000-19: An
428 updated systematic analysis with implications for the Sustainable
429 Development Goals. *Lancet Child Adolesc Health*. 2022;6:106-15.
- 430 2. Darby JB, Singh A, Quinonez R. Management of complicated pneumonia
431 in childhood: A review of recent literature. *Rev Recent Clin Trials*.
432 2017;12:253-9.
- 433 3. Gao LW, Yin J, Hu YH, Liu XY, Feng XL, He JX, et al. The epidemiology of
434 paediatric *Mycoplasma pneumoniae* pneumonia in North China: 2006 to
435 2016. *Epidemiol Infect*. 2019;147:e192.
- 436 4. Lee E, Kim CH, Lee YJ, Kim HB, Kim BS, Kim HY, et al. Annual and
437 seasonal patterns in etiologies of pediatric community-acquired
438 pneumonia due to respiratory viruses and *Mycoplasma pneumoniae*
439 requiring hospitalization in South Korea. *Bmc Infect Dis*. 2020;20:132.
- 440 5. Liu P, Xu M, Cao L, Su L, Lu L, Dong N, et al. Impact of COVID-19
441 pandemic on the prevalence of respiratory viruses in children with lower
442 respiratory tract infections in China. *Virology*. 2021;18:159.
- 443 6. Vittucci AC, Piccioni L, Coltella L, Ciarlito C, Antilici L, Bozzola E, et al.
444 The disappearance of respiratory viruses in children during the COVID-19
445 pandemic. *Int J Environ Res Public Health*. 2021;18:9550.
- 446 7. Li L, Wang H, Liu A, Wang R, Zhi T, Zheng Y, et al. Comparison of 11

- 447 respiratory pathogens among hospitalized children before and during the
448 COVID-19 epidemic in Shenzhen, China. *Viol J.* 2021;18:202.
- 449 8. Takashita E, Kawakami C, Momoki T, Saikusa M, Shimizu K, Ozawa H, et
450 al. Increased risk of rhinovirus infection in children during the coronavirus
451 disease-19 pandemic. *Influenza Other Respir Viruses.* 2021;15:488-94.
- 452 9. Agca H, Akalin H, Saglik I, Hacimustafaoglu M, Celebi S, Ener B. Changing
453 epidemiology of influenza and other respiratory viruses in the first year of
454 COVID-19 pandemic. *J Infect Public Health.* 2021;14:1186-90.
- 455 10. Wan WY, Thoon KC, Loo LH, Chan KS, Oon L, Ramasamy A, et al. Trends
456 in respiratory virus infections during the COVID-19 pandemic in singapore,
457 2020. *JAMA Netw Open.* 2021;4:e2115973.
- 458 11. Kuitunen I, Artama M, Mäkelä L, Backman K, Heiskanen-Kosma T, Renko
459 M. Effect of social distancing due to the COVID-19 pandemic on the
460 incidence of viral respiratory tract infections in children in finland during
461 early 2020. *Pediatr Infect Dis J.* 2020;39:e423-7.
- 462 12. Collaborators GLRI. Estimates of the global, regional, and national
463 morbidity, mortality, and aetiologies of lower respiratory infections in 195
464 countries, 1990-2016: A systematic analysis for the Global Burden of
465 Disease Study 2016. *Lancet Infect Dis.* 2018;18:1191-210.
- 466 13. Yun KW, Wallihan R, Juergensen A, Mejias A, Ramilo O.
467 Community-Acquired pneumonia in children: Myths and facts. *Am J*
468 *Perinatol.* 2019;36:S54-7.

- 469 14. Radhakrishnan D, Yamashita C, Gillio-Meina C, Fraser DD. Translational
470 research in pediatrics III: Bronchoalveolar lavage. *Pediatrics*.
471 2014;134:135-54.
- 472 15. Wang L, Zhao M, Shi Z, Feng Z, Guo W, Yang S, et al. A GeXP-Based
473 assay for simultaneous detection of multiple viruses in hospitalized
474 children with community acquired pneumonia. *Plos One*.
475 2016;11:e162411.
- 476 16. Midulla F, de Blic J, Barbato A, Bush A, Eber E, Kotecha S, et al. Flexible
477 endoscopy of paediatric airways. *Eur Respir J*. 2003;22:698-708.
- 478 17. Experts Group of Pediatric Respiratory Endoscopy, Talent Exchange
479 Serice Center of National Health Commission Endoscopy Committee,
480 Pediatric Section of Chinese Medical Doctor Association, Pediatric
481 Respiratory Endoscopy Committee, Endoscopists Section of Chinese
482 Medical Doctor Association, Pediatric Interventional Respirology Group,
483 Maternal and Pediatric Minimally Invasive Section of Chinese Maternal and
484 Child Health Association Bronchoscopy Collaboration Subgroup of
485 Respirology Group, Pediatric Section of Chinese Medical Associatio.
486 Guideline of pediatric flexible bronchoscopy in China (2018 version).
487 *Zhong Hua Shi Yong Er Ke Lin Chuang Za Zhi*. 2018;13:983-989.
- 488 18. Chen D, Huang Y, Jiao A, Jin R, Liu X, Meng C, et al. Expert consensus on
489 respiratory endoscopic interventional diagnosis and treatment of refractory
490 pneumonia in Chinese children. *Zhong Hua Shi Yong Er Ke Za Zhi*.

- 491 2019;34:449-57.
- 492 19. Andronikou S, Goussard P, Sorantin E. Computed tomography in children
493 with community-acquired pneumonia. *Pediatr Radiol*. 2017;47:1431-40.
- 494 20. Rhedin S, Lindstrand A, Hjelmgren A, Ryd-Rinder M, Ohrmalm L,
495 Tolfvenstam T, et al. Respiratory viruses associated with
496 community-acquired pneumonia in children: Matched case-control study.
497 *Thorax*. 2015;70:847-53.
- 498 21. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al.
499 Community-acquired pneumonia requiring hospitalization among U.S.
500 Children. *N Engl J Med*. 2015;372:835-45.
- 501 22. Zhang C, Zhu N, Xie Z, Lu R, He B, Liu C, et al. Viral etiology and clinical
502 profiles of children with severe acute respiratory infections in China. *Plos*
503 *One*. 2013;8:e72606.
- 504 23. Kenmoe S, Tchendjou P, Vernet MA, Moyo-Tetang S, Mossus T,
505 Njankouo-Ripa M, et al. Viral etiology of severe acute respiratory infections
506 in hospitalized children in Cameroon, 2011-2013. *Influenza Other Respir*
507 *Viruses*. 2016;10:386-93.
- 508 24. Guo W, Cui X, Wang Q, Wei Y, Guo Y, Zhang T, et al. Clinical evaluation of
509 metagenomic next-generation sequencing for detecting pathogens in
510 bronchoalveolar lavage fluid collected from children with
511 community-acquired pneumonia. *Front Med (Lausanne)*. 2022;9:952636.
- 512 25. Spuesens EB, Fraaij PL, Visser EG, Hoogenboezem T, Hop WC, van

- 513 Adrichem LN, et al. Carriage of *Mycoplasma pneumoniae* in the upper
514 respiratory tract of symptomatic and asymptomatic children: An
515 observational study. *Plos Med*. 2013;10:e1001444.
- 516 26. Li YT, Liang Y, Ling YS, Duan MQ, Pan L, Chen ZG. The spectrum of viral
517 pathogens in children with severe acute lower respiratory tract infection:
518 A 3-year prospective study in the pediatric intensive care unit. *J Med Virol*.
519 2019;91:1633-42.
- 520 27. Kutty PK, Jain S, Taylor TH, Bramley AM, Diaz MH, Ampofo K, et al.
521 *Mycoplasma pneumoniae* Among Children Hospitalized with
522 Community-acquired Pneumonia. *Clin Infect Dis*. 2019;68:5-12.
- 523 28. Huang L, Huang X, Jiang W, Zhang R, Yan Y, Huang L. Independent
524 predictors for longer radiographic resolution in patients with refractory
525 *Mycoplasma pneumoniae* pneumonia: A prospective cohort study. *Bmj*
526 *Open*. 2018;8:e23719.
- 527 29. Wang L, Wang W, Sun JM, Ni SW, Ding JL, Zhu YL, et al. Efficacy of
528 fiberoptic bronchoscopy and bronchoalveolar lavage in childhood-onset,
529 complicated plastic bronchitis. *Pediatr Pulmonol*. 2020;55:3088-95.